Bone Biologics Secures $3 Million Financing Through Private Placement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 11 hours ago
0mins
Source: Newsfilter
- Financing Agreement: Bone Biologics has entered into an agreement with a single healthcare-focused institutional investor to issue 2,112,677 shares of common stock and related warrants, with total expected proceeds of approximately $3 million, reflecting market confidence in its orthobiologic products.
- Warrant Details: The financing includes Series F and Series G warrants, both priced at $1.42 per share, and if fully exercised, could provide an additional $6 million in potential proceeds, thereby strengthening the company's capital structure.
- Clear Use of Funds: The company intends to use the proceeds for clinical trials, maintaining its patent portfolio, and general working capital, indicating a strong commitment to ongoing investment and development in the bone regeneration sector to expedite product commercialization.
- Compliance and Risk Advisory: The securities are offered under Section 4(a)(2) of the Securities Act of 1933, and the unregistered securities may face trading restrictions, prompting investors to be aware of associated risks and market condition changes to ensure sound investment decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BBLG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BBLG
About BBLG
Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bone Biologics Secures $3M Private Placement Agreement
- Financing Agreement: Bone Biologics Corporation has entered into a definitive agreement with a healthcare-focused institutional investor, expected to yield $3 million in initial gross proceeds, reflecting market confidence in its business.
- Share Sale Details: The private placement involves the sale of 2.11 million shares of common stock or pre-funded warrants at a purchase price of $1.42 per share, indicating the company's pricing power in the capital markets.
- Potential Gains from Warrants: The transaction also includes equal tranches of five-year Series F and 18-month Series G warrants, which could secure an additional $6 million in gross proceeds if fully exercised, further strengthening the company's financial position.
- Planned Use of Funds: Bone Biologics intends to utilize the net proceeds to fund ongoing clinical trials, maintain and extend its patent portfolio, and support working capital and general corporate requirements, demonstrating its strategic focus on future growth.
See More
Bone Biologics Secures $3 Million Investment Agreement
- Financing Agreement: Bone Biologics Corporation has entered into a definitive agreement with a single healthcare investor to issue 2.11 million shares of common stock and related warrants, expected to generate approximately $3 million, with potential for an additional $6 million if warrants are fully exercised, enhancing the company's financial capacity to support clinical trials and patent maintenance.
- Warrant Details: The Series F and G warrants are exercisable at $1.42 per share, with the F warrants having a five-year term and the G warrants expiring in 18 months, providing investors with future opportunities to participate in the company's growth.
- Market Performance Analysis: BBLG's stock has traded between $1.05 and $4.13 over the past year, closing at $1.47, down 2.78%, but rising 16.33% to $1.71 in after-hours trading, indicating a positive market reaction to the financing news.
- Use of Funds Planning: Bone Biologics intends to use the proceeds for clinical trials, patent portfolio maintenance, and general working capital, reflecting the company's strategic decision to enhance its market competitiveness through business expansion and technology development.
See More
Bone Biologics Secures $3 Million Financing Through Private Placement
- Financing Agreement: Bone Biologics has entered into an agreement with a single healthcare-focused institutional investor to issue 2,112,677 shares of common stock and related warrants, with total expected proceeds of approximately $3 million, reflecting market confidence in its orthobiologic products.
- Warrant Details: The financing includes Series F and Series G warrants, both priced at $1.42 per share, and if fully exercised, could provide an additional $6 million in potential proceeds, thereby strengthening the company's capital structure.
- Clear Use of Funds: The company intends to use the proceeds for clinical trials, maintaining its patent portfolio, and general working capital, indicating a strong commitment to ongoing investment and development in the bone regeneration sector to expedite product commercialization.
- Compliance and Risk Advisory: The securities are offered under Section 4(a)(2) of the Securities Act of 1933, and the unregistered securities may face trading restrictions, prompting investors to be aware of associated risks and market condition changes to ensure sound investment decisions.
See More
Bone Biologics Extends rhNELL-1 Product Shelf Life to 24 Months
- Product Shelf Life Extension: Bone Biologics successfully extended the shelf life of its rhNELL-1 protein product to 24 months, which not only enhances manufacturing efficiency but also improves supply chain flexibility, supporting clinical readiness.
- Strengthened Capital Structure: The company completed a $5 million registered public offering in Q2 2025, providing funding to support ongoing clinical development activities and intellectual property initiatives, ensuring stability in capital markets.
- Intellectual Property Expansion: Bone Biologics filed a U.S. patent application related to its bone regeneration technology, further strengthening its proprietary platform and enhancing long-term value in the competitive landscape.
- Nasdaq Compliance Restored: The company regained compliance with Nasdaq's minimum bid price requirement in June 2025, reinforcing its ability to access public capital markets continuously.
See More
Bone Biologics Extends rhNELL-1 Product Shelf Life to 24 Months
- Shelf Life Extension: Bone Biologics announces that the shelf life of its rhNELL-1 product has been extended to 24 months, based on ongoing stability data, representing a logical progression from prior 12- and 18-month milestones.
- Manufacturing Efficiency Improvement: The extended shelf life is expected to enhance manufacturing efficiency, inventory management, and supply chain flexibility, thereby supporting clinical and commercial readiness as the company advances product development.
- Accelerated Commercialization: CEO Jeff Frelick states that this milestone is an important step toward commercialization, expected to support disciplined capital deployment and long-term shareholder value creation.
- Bone Regeneration Technology Development: Bone Biologics is developing rhNELL-1 as a differentiated bone growth factor designed to promote bone regeneration in hard-to-heal fusion settings, further solidifying its competitive position in the spinal fusion market.
See More
Bone Biologics Announces Closing of $5.0 Million Public Offering
Public Offering Announcement: Bone Biologics Corporation has completed a public offering of 1,250,000 shares of common stock and accompanying warrants, raising $5 million in gross proceeds, with potential additional proceeds of $10 million from warrant exercises.
Use of Proceeds: The company plans to use the net proceeds for funding clinical trials, maintaining its patent portfolio, and general corporate purposes, while also focusing on regenerative medicine for bone and spinal fusion procedures.
See More
Bone Biologics Secures $3M Private Placement Agreement
- Financing Agreement: Bone Biologics Corporation has entered into a definitive agreement with a healthcare-focused institutional investor, expected to yield $3 million in initial gross proceeds, reflecting market confidence in its business.
- Share Sale Details: The private placement involves the sale of 2.11 million shares of common stock or pre-funded warrants at a purchase price of $1.42 per share, indicating the company's pricing power in the capital markets.
- Potential Gains from Warrants: The transaction also includes equal tranches of five-year Series F and 18-month Series G warrants, which could secure an additional $6 million in gross proceeds if fully exercised, further strengthening the company's financial position.
- Planned Use of Funds: Bone Biologics intends to utilize the net proceeds to fund ongoing clinical trials, maintain and extend its patent portfolio, and support working capital and general corporate requirements, demonstrating its strategic focus on future growth.
See More
Bone Biologics Secures $3 Million Investment Agreement
- Financing Agreement: Bone Biologics Corporation has entered into a definitive agreement with a single healthcare investor to issue 2.11 million shares of common stock and related warrants, expected to generate approximately $3 million, with potential for an additional $6 million if warrants are fully exercised, enhancing the company's financial capacity to support clinical trials and patent maintenance.
- Warrant Details: The Series F and G warrants are exercisable at $1.42 per share, with the F warrants having a five-year term and the G warrants expiring in 18 months, providing investors with future opportunities to participate in the company's growth.
- Market Performance Analysis: BBLG's stock has traded between $1.05 and $4.13 over the past year, closing at $1.47, down 2.78%, but rising 16.33% to $1.71 in after-hours trading, indicating a positive market reaction to the financing news.
- Use of Funds Planning: Bone Biologics intends to use the proceeds for clinical trials, patent portfolio maintenance, and general working capital, reflecting the company's strategic decision to enhance its market competitiveness through business expansion and technology development.
See More
Bone Biologics Secures $3 Million Financing Through Private Placement
- Financing Agreement: Bone Biologics has entered into an agreement with a single healthcare-focused institutional investor to issue 2,112,677 shares of common stock and related warrants, with total expected proceeds of approximately $3 million, reflecting market confidence in its orthobiologic products.
- Warrant Details: The financing includes Series F and Series G warrants, both priced at $1.42 per share, and if fully exercised, could provide an additional $6 million in potential proceeds, thereby strengthening the company's capital structure.
- Clear Use of Funds: The company intends to use the proceeds for clinical trials, maintaining its patent portfolio, and general working capital, indicating a strong commitment to ongoing investment and development in the bone regeneration sector to expedite product commercialization.
- Compliance and Risk Advisory: The securities are offered under Section 4(a)(2) of the Securities Act of 1933, and the unregistered securities may face trading restrictions, prompting investors to be aware of associated risks and market condition changes to ensure sound investment decisions.
See More
Bone Biologics Extends rhNELL-1 Product Shelf Life to 24 Months
- Product Shelf Life Extension: Bone Biologics successfully extended the shelf life of its rhNELL-1 protein product to 24 months, which not only enhances manufacturing efficiency but also improves supply chain flexibility, supporting clinical readiness.
- Strengthened Capital Structure: The company completed a $5 million registered public offering in Q2 2025, providing funding to support ongoing clinical development activities and intellectual property initiatives, ensuring stability in capital markets.
- Intellectual Property Expansion: Bone Biologics filed a U.S. patent application related to its bone regeneration technology, further strengthening its proprietary platform and enhancing long-term value in the competitive landscape.
- Nasdaq Compliance Restored: The company regained compliance with Nasdaq's minimum bid price requirement in June 2025, reinforcing its ability to access public capital markets continuously.
See More
Bone Biologics Extends rhNELL-1 Product Shelf Life to 24 Months
- Shelf Life Extension: Bone Biologics announces that the shelf life of its rhNELL-1 product has been extended to 24 months, based on ongoing stability data, representing a logical progression from prior 12- and 18-month milestones.
- Manufacturing Efficiency Improvement: The extended shelf life is expected to enhance manufacturing efficiency, inventory management, and supply chain flexibility, thereby supporting clinical and commercial readiness as the company advances product development.
- Accelerated Commercialization: CEO Jeff Frelick states that this milestone is an important step toward commercialization, expected to support disciplined capital deployment and long-term shareholder value creation.
- Bone Regeneration Technology Development: Bone Biologics is developing rhNELL-1 as a differentiated bone growth factor designed to promote bone regeneration in hard-to-heal fusion settings, further solidifying its competitive position in the spinal fusion market.
See More
Bone Biologics Announces Closing of $5.0 Million Public Offering
Public Offering Announcement: Bone Biologics Corporation has completed a public offering of 1,250,000 shares of common stock and accompanying warrants, raising $5 million in gross proceeds, with potential additional proceeds of $10 million from warrant exercises.
Use of Proceeds: The company plans to use the net proceeds for funding clinical trials, maintaining its patent portfolio, and general corporate purposes, while also focusing on regenerative medicine for bone and spinal fusion procedures.
See More
